Why Solid Biosciences Stock Is Trading Higher Today

Solid Biosciences SLDB shares are trading higher on Thursday after the company announced the FDA has lifted the clinical hold placed on the company's IGNITE DMD Phase 1/2 clinical trial.

Solid Biosciences is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age.

Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. In the assistive device program, the company focuses on producing a wearable assistive device for patients with DMD.

Solid Biosciences shares traded up 121.67% to $4.50 on Thursday. The stock has a 52-week high of $13.58 and a 52-week low of $1.93.

$SLDB Solid Biosciences Inc +140% Move Of The Day | Benzinga Pro Alert https://t.co/km5ZOt4CHU via @YouTube

— Benzinga (@Benzinga) October 1, 2020